Target intelligence / Profile preview

Ribosomal protein L21 pseudogene 125 (RPL21P125)

Target
RPL21P125
Molecular classification
Other (Pseudogene)
01

Overview

Ribosomal protein L21 pseudogene 125 (RPL21P125) is a processed pseudogene; it does not encode a functional protein and is not an active component of the ribosome or involved in protein synthesis. Pseudogenes are typically non-functional remnants of genes that have lost their ability to code for a protein, and they are common for ribosomal protein genes due to their evolutionary history. As such, RPL21P125 is not a therapeutic target, does not have a known biological function, disease association, or pharmacological relevance [1][4]. The functional gene in this family is ribosomal protein L21 (RPL21), which encodes a protein component of the 60S large ribosomal subunit [3][4]. Multiple pseudogenes for ribosomal proteins exist, including many with similar names, but these are generally non-functional [3][4]. There is something "wrong" with this target for drug discovery purposes: as a pseudogene, RPL21P125 is not a therapeutically relevant molecule and does not serve as a receptor, enzyme, transporter, or any other typical molecular drug target [1][4]. Direct genetic information for pseudogenes such as RPL21P125 is limited to gene product catalogs and databases, with no evidence for biological function or disease association [1]. The functional RPL21 gene codes for a structurally relevant ribosomal protein [3][4], but pseudogenes like RPL21P125 are non-coding, non-therapeutic, and not of practical clinical or research utility.

Other names
RPL21P125RPL21_55_1506

Beyond the preview

Go deeper on Ribosomal protein L21 pseudogene 125 (RPL21P125).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L21 pseudogene 125 (RPL21P125).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call